Hydagelan (Hydromorphone Hydrochloride)

Hydagelan is indicated for the management of severe pain that requires an opioid analgesic.

• Severe acute pain, for example pain resulting from traumatic injury, burns, or acute medical conditions.
• Post‑operative pain after major surgical procedures where strong analgesia is required during the immediate recovery period.
• Pain related to cancer or other malignant diseases when less potent analgesics do not provide adequate control.
• Opioid‑tolerant patients who need rapid‑onset analgesia, administered intravenously or subcutaneously for quick pain relief.
• Adjunctive treatment for breakthrough pain episodes in patients already receiving a baseline opioid regimen.

• Hydagelan delivers hydromorphone hydrochloride, a potent μ‑opioid receptor agonist. After intravenous or subcutaneous injection, the drug crosses the blood‑brain barrier and binds selectively to μ‑opioid receptors in the central nervous system. This binding inhibits adenylate cyclase activity, reduces cyclic AMP levels, and promotes opening of potassium channels while closing calcium channels, leading to decreased neuronal excitability and inhibition of pain signal transmission.

Like other opioid analgesics, Hydagelan may be associated with a range of adverse reactions, which are typically categorized by frequency and severity.

Common

• Nausea, vomiting, or loss of appetite, often occurring shortly after dosing.
• Constipation or reduced gastrointestinal motility, which may require laxative support.
• Drowsiness, sedation, or mild dizziness that can affect alertness.
• Dry mouth and mild itching or erythema at the injection site.

Serious

• Respiratory depression, characterized by slowed or shallow breathing, which can be life‑threatening.
• Severe hypotension or cardiovascular collapse, presenting as marked drop in blood pressure.
• Development of physical dependence, tolerance, or opioid use disorder with prolonged therapy.

When prescribing or administering Hydagelan, clinicians should observe several precautionary measures to minimize risk and ensure safe use.

• Assess the patient’s respiratory status before initiating therapy and monitor continuously during treatment.
• Use the lowest effective dose and limit duration, especially in opioid‑naïve individuals.
• Avoid use in patients with known hypersensitivity to hydromorphone or other opioid analgesics.
• Exercise caution in patients with compromised renal or hepatic function, as clearance may be reduced.
• Consider the potential for sedation and impaired mental status; advise patients not to operate machinery or drive.
• Evaluate for a history of substance use disorder and implement appropriate risk‑mitigation strategies.

Hydagelan can interact with other medications, altering its analgesic effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other central nervous system depressants such as benzodiazepines, barbiturates, or high‑dose antihistamines.
• Co‑administration with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy.

Use with caution

• Mixed agonist‑antagonist opioids (e.g., buprenorphine) which may precipitate withdrawal.
• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs) due to risk of serotonin syndrome.
• Drugs that inhibit CYP3A4 or CYP2D6, potentially affecting hydromorphone metabolism.
• Anticholinergic agents that may exacerbate constipation.